Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00572481 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Axillary Reverse Mapping

Study acronym: ARM
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date: Oct 2025 to Oct 2026
    • Study completion date: Nov 2026 to Nov 2027
    v34
  2. Minor Primary completion date: Aug 2025 to Oct 2025
    • Study completion date: Feb 2026 to Nov 2026
    • Publications: details revised at 3 of 5 entries
    v33
  3. Minor Primary completion date: Feb 2025 to Aug 2025
    • Study completion date: Aug 2025 to Feb 2026
    • Publications: details revised at 3 of 5 entries
    v32
  4. Minor Re-verified, no change to tracked fieldsv31
  5. Notable Primary completion date: Feb 2024 to Feb 2025
    • Study completion date: Aug 2024 to Aug 2025
    v30
Show 28 earlier versionsHide 28 earlier versions
  1. Minor Primary completion date: Dec 2023 to Feb 2024
    • Study completion date: Jun 2024 to Aug 2024
    v29
  2. Minor Primary completion date: Jun 2023 to Dec 2023v28
  3. Minor Primary completion date: Jan 2023 to Jun 2023
    • Study completion date: Jun 2023 to Jun 2024
    v27
  4. Notable Primary completion date: Jan 2022 to Jan 2023
    • Study completion date: Jun 2022 to Jun 2023
    v26
  5. Notable Primary completion date: Jan 2021 to Jan 2022
    • Study completion date: Jan 2021 to Jun 2022
    v25
  6. Minor Primary and study completion dates: Sep 2020 to Jan 2021v24
  7. Minor Primary and study completion dates: May 2020 to Sep 2020v23
  8. Notable Primary and study completion dates: May 2019 to May 2020v22
  9. Minor 2 versions Re-verified since Aug 30, 2017, no change to tracked fieldsv20-v21
  10. Notable Primary completion date: May 2017 to May 2019
    • Study completion date: May 2018 to May 2019
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study arms: 1 to 2
    v19
  11. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v18
  12. Minor Re-verified, no change to tracked fieldsv17
  13. Notable Primary completion date: May 2016 to May 2017
    • Study completion date: May 2017 to May 2018
    v16
  14. Notable Primary completion date: May 2015 to May 2016
    • Study completion date: May 2016 to May 2017
    v15
  15. Minor Publications: 4 to 5v14
  16. Minor Re-verified, no change to tracked fieldsv13
  17. Notable Primary completion date: May 2014 to May 2015
    • Study completion date: May 2015 to May 2016
    v12
  18. Minor 3 versions Re-verified since Jan 17, 2012, no change to tracked fieldsv9-v11
  19. Notable Primary completion date: May 2012 to May 2014
    • Study completion date: Nov 2012 to May 2015
    v8
  20. Minor Publications: 3 to 4v7
  21. Minor 2 versions Re-verified since Jan 8, 2010, no change to tracked fieldsv5-v6
  22. Minor Publications: 1 to 3v4
  23. Minor Re-verified, no change to tracked fieldsv3
  24. Minor Primary completion date: May 2012
    • Study completion date: May 2012 to Nov 2012
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
We hypothesize that variations in anatomic location of the arm lymphatic drainage system put the arm lymphatics at risk for disruption during a SLNB and / or ALND. Therefore, mapping the drainage of the arm during the procedure would decrease the likelihood of inadvertent disruption of the lymphatics and the subsequent development of lymphedema. A combination of radioactivity and blue dye will be used.
Trial Details
NCT Number NCT00572481
Lead Sponsor University of Arkansas
Conditions
(from sponsor)
Cancer of the Breast
Related terms Breast Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov